| 000 | 01217 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515064741.0 | ||
| 264 | 0 | _c20070801 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a1472-4472 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHamdy, Neveen A T | |
| 245 | 0 | 0 |
_aTargeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. _h[electronic resource] |
| 260 |
_bCurrent opinion in investigational drugs (London, England : 2000) _cApr 2007 |
||
| 300 |
_a299-303 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aOsteoporosis _xdrug therapy |
| 650 | 0 | 4 | _aRANK Ligand |
| 650 | 0 | 4 |
_aReceptor Activator of Nuclear Factor-kappa B _ximmunology |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 773 | 0 |
_tCurrent opinion in investigational drugs (London, England : 2000) _gvol. 8 _gno. 4 _gp. 299-303 |
|
| 999 |
_c17007368 _d17007368 |
||